Clinical Trial Update: Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of bortezomib, cladribine, and rituximab in advanced mantle cell lymphoma or indolent lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Lymphoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Cladribine (cladribine)
• Rituximab (rituximab)

Snippet

Sponsor: University of Arizona | Conditions: Lymphoma, Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2019-10-22